𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The effect of a lymphotoxic factor from patients with multiple sclerosis on acute lymphosarcoma cell leukemia and acute lymphoblastic leukemia

✍ Scribed by Armentrout, Steven A. ;White, Gregory ;Van Den Noort, Stanley

Publisher
John Wiley and Sons
Year
1975
Tongue
English
Weight
366 KB
Volume
1
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Eight patients with acute lymphosarcoma cell leukemia or acute lymphoblastic leukemia received infusions of plasma containing a lymphotoxic factor. The lymphotoxic factor induced a transient fall in the number of β€œblast” cell forms in the peripheral blood in six of the eight patients but did not produce sustained remissions.

Previous investigations have demonstrated that this lymphotoxic factor, found in the plasma of patients with active multiple sclerosis, is of low molecular weight and does not have the properties normally associated with an antibody. This factor appears to selectively interfere with ribonucleic acid synthesis in the thymusderived lymphocyte. Lymphotoxic factor activity was demonstrated in the serum of one patient during a remission in leukemia induced by a viral illness.

πŸ“œ SIMILAR VOLUMES

The low frequency of defective TPMT alle
The low frequency of defective TPMT alleles in Turkish population: A study on pediatric patients with acute lymphoblastic leukemia
✍ Tugba Boyunegmez Tumer; Gulen Ulusoy; Orhan Adali; Gurses Sahin; Sevgi Gozdasogl πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 2 views

## Abstract 6‐Mercaptopurine (6MP) is an essential anticancer drug used in the treatment of childhood acute lymphoblastic leukemia (ALL). Thiopurine methyltransferase (TPMT) polymorphisms are the major determinants of interindividual differences in the severe toxicity or efficacy of 6MP. Four varia

Treatment of patients with acute lymphob
Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features : Randomized controlled trial from the Children's Cancer Group
✍ Peter G. Steinherz; Paul S. Gaynon; John C. Breneman; Joel M. Cherlow; Neil J. G πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 211 KB πŸ‘ 3 views

## Background: Children with acute lymphoblastic leukemia with multiple poor prognostic factors and who have a lymphomatous mass at diagnosis, whether of t- or non-t-immunophenotype, are at increased risk of short term remission and extramedullary recurrence, and are in need of better therapies. #